Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth.

被引：0

作者：

Maity, Sankar N.

Wu, Guanglin

Lu, Jing-Fang

Anh Hoang

Landesman, Yosef

McCauley, Dilara

Carlson, Robert

Rashal, Tami

Shacham, Sharon

Broom, Bradley McIntosh

Baggerly, Keith A.

Aparicio, Ana

Efstathiou, Eleni

Araujo, John C.

Logothetis, Christopher

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Karyopharm Therapeut Inc, Natick, MA USA

[3] Karyopharm Therapeut Inc, Newton, MA USA

[4] Optimata, Ramat Gan, Israel

[5] Univ Athens, Alexandra Gen Hosp Athens, Dept Oncol, Dept Clin Therapeut, Athens, Greece

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期

关键词：

D O I：

10.1200/jco.2015.33.7_suppl.277

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

277

引用

页数：1

共 9 条

[1] Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer
Maity, Sankar Narayan
Wu, Guanglin
Lu, Jing-Fang
Hoang, Anh
Landesman, Yosef
McCauley, Dilara
Shacham, Sharon
Kauffman, Michael G.
Aparicio, Ana M.
Efstathiou, Eleni
Araujo, John C.
Logothetis, Christopher J.
CANCER RESEARCH, 2014, 74 (19)
[2] ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), ± DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA
Chen, C.
Gutierrez, M.
Brown, P.
Gabrail, N.
Baz, R.
Reece, D.
Flinn, I.
Trudel, S.
Siegel, D.
Mau-Sorensen, M.
Kuruvilla, J.
Carlson, R.
McCauley, D.
Shacham, E.
Saint-Martin, J. R.
McCartney, J.
Marshall, T.
Landesman, Y.
Friedlander, S.
Pond, G.
Rebello, S.
Rashal, T.
Shacham, S.
Kauffman, M.
Mirza, M.
HAEMATOLOGICA, 2014, 99 : 359 - 359
[3] Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin I (XPOI) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
Martignetti, John
Razak, Albiruni R. A.
Chen, Ying
Gabrail, Nashat Y.
Gerecitano, John F.
Camacho, Catalina
Pereira, Elena
Dottino, Peter Remsen
Shacham, Sharon
McCauley, Dilara
Rashal, Tami
Saint-Martin, Jean-Richard
Shacham, Eran
Vincett, Darcy
Kauffman, Michael
Mirza, Mansoor Raza
Sorensen, Morten
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Kase, Adam M.
Gleba, Justyna
Miller, James L.
Miller, Erin
Petit, Joachim
Barrett, Michael T.
Zhou, Yumei
Parent, Ephraim E.
Cai, Hancheng
Knight, Joshua A.
Orme, Jacob
Reynolds, Jordan
Durham, William F.
Metz, Thomas M.
Meurice, Nathalie
Edenfield, Brandy
Demirer, Aylin Alasonyalilar
Bilgili, Ahmet
Hickman, Peyton G.
Pawlush, Matthew L.
Marlow, Laura
Wickland, Daniel P.
Tan, Winston
Copland III, John A.
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06) : 823 - 835
[5] PRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA)
Martignetti, J.
Razak, A. R. A.
Chen, Y.
Gabrail, N. Y.
Gericitano, J. F.
Camacho, C.
Pereira, E.
Evans, B.
Dottino, P.
McCauley, D.
Shacham, S.
Rashal, T.
Saint-Martin, J.
Shacham, E.
Vincent, D.
Kauffman, M.
Mirza, M. R.
Mau-Sorensen, M.
ANNALS OF ONCOLOGY, 2014, 25
[6] Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lyphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Kuruvilla, John
Gutierrez, Martin
Shah, Bijal D.
Gabrail, Nashat Y.
Brown, Peter de Nully
Stone, Richard M.
Garzon, Ramiro
Savona, Michael
Siegel, David S.
Baz, Rachid
Mau-Sorensen, Morten
Davids, Matthew S.
Byrd, John C.
Shacham, Sharon
Rashal, Tami
Yau, Cindy Y. F.
McCauley, Dilara
Saint-Martin, Jean-Richard
McCartney, John
Landesman, Yosef
Klebanov, Boris
Pond, Greg
Oza, Amit M.
Kauffman, Michael
Mirza, Mansoor R.
BLOOD, 2013, 122 (21)
[7] Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)
Chen, Christine I.
Gutierrez, Martin
Brown, Peter de Nully
Gabrail, Nashat
Baz, Rachid
Reece, Donna E.
Savona, Michael
Trudel, Suzanne
Siegel, David S.
Mau-Sorensen, Morten
Kuruvilla, John
Byrd, John C.
Shacham, Sharon
Rashal, Tami
Yau, Cindy Y. F.
McCauley, Dilara
Landesman, Yosef
Klebanov, Boris
Pond, Greg
Oza, Amit M.
Kauffman, Michael
Mirza, Mansoor R.
BLOOD, 2013, 122 (21)
[8] Effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant prostate cancer model 22Rv1.
Markowski, Mark Christopher
Getzenberg, Robert H.
Steiner, Mitchell S.
Azad, Nilofer Saba
Gaillard, Stephanie
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] The effect of VERU-111, a novel oral inhibitor of a and β tubulin, on tumor growth in the human castration-resistant, AR-variant prostate cancer (PCa) model 22Rv1.
Markowski, Mark Christopher
Getzenberg, Robert H.
Steiner, Mitchell S.
Azad, Nilofer Saba
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

← 1 →